The progress of prophylactic treatment in retinopathy of prematurity

Area of Science:

• Ophthalmology
• Neonatology
• Developmental Biology

Background:

• Retinopathy of prematurity (ROP) is a significant cause of vision loss in premature infants.
• Current treatments for ROP primarily target retinal neovascularization, which occurs late in the disease process.
• Abnormal retinal vascular development, rather than just neovascularization, is increasingly recognized as a key factor in ROP pathogenesis.

Purpose of the Study:

• To review recent research on the pathogenesis of ROP occurring prior to retinal neovascularization.
• To discuss preclinical and clinical studies on preventive treatments for early stages of ROP and its animal model, oxygen-induced retinopathy (OIR).
• To highlight the importance of early-stage mechanisms and signaling pathways in ROP development and identify future therapeutic targets.

Main Methods:

• Review of existing literature on oxygen-induced retinopathy (OIR) and human ROP studies.
• Analysis of research focusing on pathological changes and molecular mechanisms preceding retinal neovascularization.
• Examination of preclinical and clinical data on early-stage ROP interventions.

Main Results:

• Early pathogenesis of ROP involves abnormal retinal vascular development, not solely neovascularization.
• Understanding pre-neovascularization mechanisms offers opportunities for novel therapeutic strategies.
• Research indicates potential for preventive treatments targeting early developmental stages.

Conclusions:

• Shifting focus from treating neovascularization to understanding early pathogenesis is essential for effective ROP intervention.
• Identifying novel targets in early retinal vascular development can lead to strategies promoting healthy blood vessel growth.
• Further research into early-stage OIR and ROP mechanisms is vital for developing proactive treatments to prevent vision impairment in premature infants.